Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Kala Pharmaceuticals Inc (KALA)
Kala Pharmaceuticals Inc (KALA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,348
  • Shares Outstanding, K 2,349
  • Annual Sales, $ 3,890 K
  • Annual Income, $ -44,820 K
  • 60-Month Beta -1.56
  • Price/Sales 8.91
  • Price/Cash Flow N/A
  • Price/Book 1.64
Trade KALA with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 78.27%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -3.19
  • Number of Estimates 3
  • High Estimate 0.50
  • Low Estimate -5.32
  • Prior Year -19.00
  • Growth Rate Est. (year over year) +83.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.20 +5.99%
on 05/01/23
19.35 -22.24%
on 05/18/23
+0.07 (+0.47%)
since 04/26/23
3-Month
9.27 +62.33%
on 03/02/23
24.00 -37.29%
on 03/08/23
+3.55 (+30.87%)
since 02/24/23
52-Week
3.54 +324.61%
on 12/23/22
56.72 -73.47%
on 01/04/23
-2.31 (-13.31%)
since 05/26/22

Most Recent Stories

More News
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate

Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.

CRSP : 64.66 (+1.27%)
KALA : 15.05 (+1.96%)
ALLO : 5.53 (+1.10%)
DRMA : 1.6200 (-13.37%)
VYNE Gains on Preclinical Data for IPF Candidate

VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.

CRSP : 64.66 (+1.27%)
KALA : 15.05 (+1.96%)
ALLO : 5.53 (+1.10%)
VYNE : 6.60 (-6.52%)
Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag

Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.

CRSP : 64.66 (+1.27%)
MDGL : 284.88 (+1.17%)
KALA : 15.05 (+1.96%)
ALLO : 5.53 (+1.10%)
Gamida Cell (GMDA) Surges on FDA Approval for Omisirge

Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.

CRSP : 64.66 (+1.27%)
KALA : 15.05 (+1.96%)
ALLO : 5.53 (+1.10%)
GMDA : 1.9600 (-1.01%)
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia

Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.

CRSP : 64.66 (+1.27%)
HGEN : 0.1497 (+1.70%)
KALA : 15.05 (+1.96%)
ALLO : 5.53 (+1.10%)
Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate

Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.

TEVA : 7.45 (+1.64%)
KALA : 15.05 (+1.96%)
ALLO : 5.53 (+1.10%)
ALVO : 8.04 (+6.35%)
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429

Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.

RGLS : 1.3400 (+0.75%)
CRSP : 64.66 (+1.27%)
KALA : 15.05 (+1.96%)
ALLO : 5.53 (+1.10%)
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug

Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.

CRSP : 64.66 (+1.27%)
KALA : 15.05 (+1.96%)
ALLO : 5.53 (+1.10%)
PBLA : 0.3360 (-6.64%)
Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News

Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.

MRNA : 126.24 (-0.18%)
IFRX : 4.16 (+1.46%)
KALA : 15.05 (+1.96%)
KALA Up on Fast Track Designation to Lead Ocular Candidate

KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.

NVO : 162.97 (+0.33%)
LGND : 72.13 (+0.63%)
KALA : 15.05 (+1.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes,...

See More

Key Turning Points

3rd Resistance Point 16.46
2nd Resistance Point 16.16
1st Resistance Point 15.60
Last Price 15.05
1st Support Level 14.75
2nd Support Level 14.45
3rd Support Level 13.89

See More

52-Week High 56.72
Fibonacci 61.8% 36.41
Fibonacci 50% 30.13
Fibonacci 38.2% 23.86
Last Price 15.05
52-Week Low 3.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar